FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: First Treatment Option for Patients

Executive Brief

News Report

The News: FDA approves dupilumab for allergic fungal rhinosinusitis.
Clinical Win: First treatment option for patients with AFRS.
Target Specialty: Otolaryngology

Key Data at a Glance

FDA Approval Date: February 24, 2026
Study Duration: 52 weeks
Trial Enrollment: 300 patients

The FDA has approved dupilumab (Dupixent) for the treatment of allergic fungal rhinosinusitis (AFRS) in adult and pediatric patients aged 6 years and older with a history of sino-nasal surgery. This approval marks the first treatment option for this condition, which can lead to serious complications if left untreated. The announcement was made on February 24, 2026.

Clinical Context

Allergic fungal rhinosinusitis (AFRS) is a rare form of chronic sinus inflammation caused by an allergic reaction to fungi in the sinuses. It affects approximately 8% of individuals with chronic sinus inflammation and nasal polyps, predominantly in warm, humid climates. Symptoms include thick, sticky mucus production, often described as resembling peanut butter, and can lead to significant morbidity, including sinus bone erosion, vision impairment, and even life-threatening complications if untreated. Current treatment options are limited, often relying on systemic corticosteroids and surgical interventions. Dupilumab, a monoclonal antibody targeting interleukin-4 and interleukin-13 signaling pathways, has previously been approved for other conditions such as asthma and eczema, demonstrating a favorable safety profile. The new indication for AFRS is particularly important as it addresses a significant unmet medical need in this patient population.

Key Findings

The FDA approval for dupilumab was based on a 52-week study that demonstrated significant improvements in sinus opacification as measured by CT scan scores (Lund-Mackay score) compared to placebo [1].

The trial enrolled 300 participants aged 6 years and older with AFRS and a history of sino-nasal surgery, highlighting the medication's efficacy across a broad age range [1].

Event rates showed that 40% of patients on dupilumab experienced significant symptom relief versus 15% in the placebo group [1].

The primary endpoint was the change in Lund-Mackay score from baseline to week 52, which showed a statistically significant improvement in the dupilumab group compared to placebo [1].

What This Means for Clinical Practice

Dupilumab provides a new therapeutic option for patients with allergic fungal rhinosinusitis, particularly those who have undergone sino-nasal surgery and are at risk for severe complications. Clinicians should consider this medication for patients who have not responded adequately to conventional therapies, such as systemic corticosteroids or surgery. The significant reduction in the need for systemic corticosteroids and sinus surgery over the 52-week trial period underscores the potential for dupilumab to improve patient outcomes and reduce healthcare costs associated with managing AFRS. As this indication becomes integrated into clinical practice, further research may be necessary to establish long-term outcomes and safety in diverse patient populations, particularly in children and adolescents.

Clinical Perspective

Workflow: Dupilumab's approval will prompt clinicians to reassess treatment protocols for AFRS, integrating this new option into care plans for affected patients.

Economics: By potentially reducing the need for surgical interventions and systemic corticosteroids, dupilumab may lower overall healthcare costs associated with managing AFRS.

Patient Outcomes: The introduction of dupilumab is expected to enhance patient quality of life by alleviating symptoms and preventing serious complications related to allergic fungal rhinosinusitis.

Editorial Team, Otolaryngology

References

FDA — FDA approves drug for adult and pediatric patients aged 6 and older with allergic fungal rhinosinusitis

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: First Treatment Option for Patients

Executive Brief

Key Data at a Glance

Clinical Context

Key Findings

What This Means for Clinical Practice

Clinical Perspective

References

Get weekly drug updates for Otolaryngology in your inbox.

Related Drug Updates

FDA Approves Lunsotogene Parvec-Cwha for Genetic Hearing Loss: First Gene Therapy for OTOF Variants

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: First Indication for AFRS

FDA Approves Dupilumab for Allergic Fungal Rhinosinusitis: Improved Sinus Opacification in Patients

Verified HCP Portal